

Seeing Beyond the Blot: A Critical Look at Assumptions and Raw Data Interpretation in Western Blotting

Maxwell DeNies¹, Allen Liu², and Santiago Schnell¹

¹University of Michigan Medical School

²University of Michigan College of Engineering

March 15, 2024

Abstract

Rapid advancements in technology refine our understanding of intricate biological processes, but a crucial emphasis remains on understanding the assumptions and sources of uncertainty underlying biological measurements. This is particularly critical in cell signaling research, where a quantitative understanding of the fundamental mechanisms governing these transient events is essential for drug development, given their importance in both homeostatic and pathogenic processes. Western blotting, a technique developed decades ago, remains an indispensable tool for investigating cell signaling, protein expression, and protein-protein interactions. While improvements in statistical analysis and methodology reporting have undoubtedly enhanced data quality, understanding the underlying assumptions and limitations of visual inspection in western blotting can provide valuable additional information for evaluating experimental conclusions. Using the example of agonist-induced receptor post-translational modification, we highlight the theoretical and experimental assumptions associated with western blotting and demonstrate how raw blot data can offer clues to experimental variability that may not be fully captured by statistical analyses and reported methodologies. This article is not intended as a comprehensive technical review of western blotting. Instead, we leverage an illustrative example to demonstrate how assumptions about experimental design and data normalization can be revealed within raw data and subsequently influence data interpretation.

1 **Seeing Beyond the Blot: A Critical Look at Assumptions and Raw**
2 **Data Interpretation in Western Blotting**

3
4 Maxwell S. DeNies ^a, Allen P. Liu ^{a,b}, Santiago Schnell ^{c, d,*}

5
6 ^a Cellular and Molecular Biology Graduate Program, University of Michigan Medical School,
7 Ann Arbor, Michigan, USA

8 ^b Department of Mechanical Engineering, University of Michigan, Ann Arbor, Michigan, USA

9 ^c Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA

10 ^e Department of Applied & Computational Mathematics & Statistics, University of Notre Dame,
11 Notre Dame, Indiana, USA

12 * Address correspondence to: Santiago Schnell (santiago.schnell@nd.edu)

13
14 *Manuscript type: Review*

15 *Running head title: Seeing Beyond the Blot*

16 *Abbreviations used: PTMs, post-translational modifications*

17 *Keywords: rigor; reproducibility; undergraduate and graduate research education; experimental*
18 *design; biometrology; quantitative biology; western blots; protein abundance; post-translational*
19 *modification; cell signaling*

20
21 **DECLARATIONS**

22 **Funding:** MSD thanks support from the National Science Foundation (Fellow ID: 2015196825).

23 **Conflict of interest:** The authors declare that they have no conflict of interest.

24 **Data availability:** The datasets generated/analyzed to illustrate the point of this essays are
25 available from the Dr. Allen Lui (e-mail: allenliu@umich.edu) on reasonable request.

27 **ABSTRACT**

28 Rapid advancements in technology refine our understanding of intricate biological processes, but
29 a crucial emphasis remains on understanding the assumptions and sources of uncertainty
30 underlying biological measurements. This is particularly critical in cell signaling research, where
31 a quantitative understanding of the fundamental mechanisms governing these transient events is
32 essential for drug development, given their importance in both homeostatic and pathogenic
33 processes. Western blotting, a technique developed decades ago, remains an indispensable tool
34 for investigating cell signaling, protein expression, and protein-protein interactions. While
35 improvements in statistical analysis and methodology reporting have undoubtedly enhanced data
36 quality, understanding the underlying assumptions and limitations of visual inspection in western
37 blotting can provide valuable additional information for evaluating experimental conclusions.
38 Using the example of agonist-induced receptor post-translational modification, we highlight the
39 theoretical and experimental assumptions associated with western blotting and demonstrate how
40 raw blot data can offer clues to experimental variability that may not be fully captured by
41 statistical analyses and reported methodologies. This article is not intended as a comprehensive
42 technical review of western blotting. Instead, we leverage an illustrative example to demonstrate
43 how assumptions about experimental design and data normalization can be revealed within raw
44 data and subsequently influence data interpretation.

45 INTRODUCTION

46 The ability to accurately measure biological processes and quantify their inherent uncertainty is
47 fundamental to scientific progress. Cell biology, in particular, presents unique challenges as
48 measurements span multiple scales. For instance, intracellular protein concentrations of specific
49 proteins can range from pM to nM, length of cellular structures range from nm to μm , forces
50 generated by molecular motors in the pN range, and timescale of signaling transduction events
51 from sub-seconds to hours. Biological systems also interact in complicated ways with their
52 internal and external environment, and are dynamically changing making specific attributes
53 difficult to measure. Consequently, biological measurements often yield a distribution of values.
54 Despite technical advancements in -omics approaches as well technical and analytical
55 improvements in microscopy, flow cytometry, and Western blotting, much of our understanding
56 of molecular mechanisms remains primarily semi-quantitative.

57

58 A complete biological measurement requires both a value and an assessment of its associated
59 uncertainty (1,2). While uncertainty is commonly defined as the experimental variability in a
60 measurement between replicates, in theory it is additive of all uncertainties throughout the
61 experimental process. The Guide to the Expression of Uncertainty in Measurement highlights the
62 incomplete definition of the measurand (the quantity being measured) and the underlying
63 assumptions as critical sources of uncertainty (3). Additionally, the possibility of non-
64 representative or incomplete sampling of what was intended to be measured as well as an
65 incomplete definition of the measurand are common sources of uncertainty defined within the
66 Guide to the Expression of Uncertainty in Measurement. These sources are highly relevant in
67 biological systems but can be harder to quantify. Understanding the inherent limitations within
68 any biological measurement is crucial for both experimentalists and theorists when interpreting
69 results.

70

71 Despite the emergence of alternative techniques to detect protein abundance, post-translational
72 modifications (PTMs), and cell signaling – flow cytometry, FRET biosensors, microscopy, etc.
73 (4–8) – Western blotting remains a widely used and accessible tool across biological disciplines
74 (9). Quantitative biologists extract quantitative values from Western blots to parameterized
75 models (see, (10), as an example). While improved statistical analyses and the inclusion of

76 individual data points offers transparency, carefully examining raw data, particularly for Western
77 blots or immunofluorescence images, can provide valuable insights for interpretation.

78

79 In this perspective, we examine several factors that can influence Western blot analysis and
80 interpretation. We illustrate these considerations using an example from our research (FIGURE 1),
81 which investigated the impact of CXCR4 (C-X-C chemokine receptor 4) mutations (S338/39A
82 and S324/25A) on CXCR4 expression and downstream signaling. In addition to probing for total
83 protein and GAPDH (loading controls), we employed two antibodies to detect CXCR4: the
84 commercial monoclonal antibody UMB2 and a polyclonal MYC antibody targeting an
85 incorporated MYC epitope tag (FIGURE 1). It is important to note that UMB2, initially described
86 as detecting total CXCR4, has subsequently been shown to exhibit sensitivity to CXCR4 PTMs
87 (11–13). These experiments were conducted in RPE cells overexpressing individual CXCR4
88 constructs with a C-terminal MYC tag (WT), as wildtype RPE cells have negligible endogenous
89 CXCR4 expression and are unresponsive to CXCL12 (a CXCR4 agonist) (7,12). In the following
90 sections, we discuss how loading controls, experimental timescales, antibody stripping, and
91 antibody banding patterns can shape Western blot interpretation.

92

93 This perspective does not aim to provide a comprehensive technical review of Western blotting;
94 several excellent articles offer in-depth guidance on best practice (14–22). Instead, we focus on
95 assumptions and aspects of Western blotting that should be considered by both theorists and
96 experimentalists when evaluating data.

97

98 **EXAMINING LOADING CONTROLS AND SIGNAL SATURATION IN WESTERN** 99 **BLOTTING TO SEE IF EXPERIMENTAL CONDITIONS ARE COMPERABLE**

100 Western blot analysis necessitates careful consideration of loading controls and signal linearity
101 for accurate quantitative interpretation. While housekeeping proteins like GAPDH and actin
102 remain widely used as loading controls, their expression levels can fluctuate across experimental
103 conditions (23,24,15). In the case of FIGURE 1, while loading controls appear similar within each
104 signaling time course, WT and mutant CXCR4 (S338/39A and S324/25A) samples are different.
105 While not ideal, loading protein abundance variability is relatively common in experiments
106 where multiple cell lines or +/- protein knockdown are compared due to unaccounted factors

107 such as differences in cell growth. This highlights the importance of confirming that the chosen
108 loading control remains stable under your specific experimental treatments. Ideally, total protein
109 staining should be used to normalize protein loading (25–27,15). This practice offers a more
110 reliable representation of overall protein abundance.

111
112 To ensure equal loading, it is crucial to quantify protein concentrations prior to Western blotting.
113 When comparing multiple cell lines or working with protein knockdowns, natural differences in
114 cell growth or other unaccounted factors can lead to variations in protein abundance.
115 Documenting protein concentrations alongside Western blots can help distinguish whether
116 observed differences result from experimental treatments or variations in cell health/growth.

117
118 It is also important to ensure that antibody detection falls within the linear range of the chosen
119 detection method. Oversaturated Western blot bands can lead to inaccurate quantification
120 (15,17). Prior antibody titrations with various dilutions tested against a range of sample protein
121 loads will establish optimal antibody concentrations for your experimental conditions. Image
122 acquisition systems and freely available software like *ImageJ* can aid in the detection of signal
123 saturation.

124
125 When working towards quantitative comparisons, the most robust approach is to analyze the
126 slopes obtained from linear regression analysis of the integrated optical density values of
127 immunoreactive bands across a range of increasing protein loads. This analysis should focus
128 solely on values within the linear range. Slope ratio comparisons between samples offer greater
129 reliability by correcting for inaccuracies in protein determination. This allows for more precise
130 conclusions regarding increases or decreases in protein expression compared to qualitative band
131 intensity assessments.

132
133 **Key Takeaways**

- 134 • Traditional housekeeping proteins (GAPDH, actin) can be unreliable.
- 135 • Opt for total protein staining whenever possible for more accurate normalization.
- 136 • Verify your chosen loading control remains stable under all experimental conditions.
- 137 • Quantify protein concentrations before Western blotting to ensure equal loading.

- 138 • Document protein concentrations alongside blots for informed interpretation.
- 139 • Perform antibody titrations to determine the linear range of detection.
- 140 • Use image analysis tools to check for saturation; oversaturated bands lead to inaccurate
- 141 quantification.
- 142 • Analyze slopes from integrated optical density across protein loads for the most precise
- 143 comparisons.

144

145 **ADDRESSING POST-TRANSLATIONAL MODIFICATIONS AND ANTIBODY**

146 **DETECTION IN TIME-SENSITIVE EXPERIMENTS**

147

148 In time-sensitive experiments, such as those investigating signaling mechanisms, it is crucial to

149 consider the potential impact of rapid protein modifications on antibody-based quantification.

150 This section highlights the importance of understanding antibody recognition dynamics,

151 especially within the context of PTMs.

152

153 The provided example using the UMB2 antibody to detect CXCR4 illustrates this point (FIGURE

154 1). While initially believed to detect total CXCR4, a significant decrease in detection following

155 agonist stimulation suggests otherwise. This rapid change is unlikely due to protein degradation,

156 nor is it explained by a shift in intracellular localization, as detection with an alternative MYC

157 antibody remains consistent.

158

159 The most likely explanation lies in agonist-induced CXCR4 PTMs. These modifications, well-

160 documented in the literature (25,28,29,12), can occur within the UMB2 antibody's epitope region

161 and hinder its ability to bind CXCR4. While the UMB2 antibody remains a valuable tool (11–

162 13), this example underscores the importance of understanding how PTMs or other alterations

163 can influence antibody detection and, subsequently, data interpretation.

164

165 To illustrate the impact of mutations on antibody detection, let us examine the Western blot lanes

166 (FIGURE 1; lanes 5-12). CXCR4 S338/39A and CXCR4 S324/25A are phospho-null mutant

167 receptors of biologically relevant serine residues that regulate CXCR4 internalization and

168 signaling (29). As described earlier, even minor mutations (in this case, just two residues) can

169 greatly influence CXCR4 detection with the UMB2 antibody. This is evident in FIGURE 1. We

170 found that at the 0 min time point S338/39A mutant UMB2 detection was significantly higher
171 than WT, while the S324/25A mutant UMB2 detection was negligible. Superficially, this could
172 suggest that S338/39A increases CXCR4 expression while the S324/25A mutant is poorly
173 expressed. However, investigation again with the MYC antibody clarifies that the S324/25A
174 mutant is expressed (FIGURE 1; lanes 9-12).

175

176 Again, there are several hypotheses that may explain why this occurs. It is possible that
177 S324/25A completely prevents CXCR4 UMB2 antibody detection due to a change in structure or
178 leads to a different CXCR4 PTM state within the UMB2 epitope that decreases antibody affinity.
179 In contrast, S338/39A detection with both the UMB2 and MYC antibody was elevated compared
180 to WT CXCR4 suggesting that these mutations may have attenuated degradation and possibly
181 PTM (FIGURE 1).

182

183 Further comparisons of how agonist-induced PTM is influenced by CXCR4 mutation further
184 highlights the difficulty of solely relying on these data for interpretation as incomplete stripping
185 differentially impacts the MYC detection of each of these receptors and decoupling of receptor
186 mutation from CXCR4 detectability is not possible in this data alone (FIGURE 1). These are
187 important questions that should be considered when evaluating western blots and can only be
188 fully addressed through careful consideration of raw data and potentially additional experiments.
189 In this case, the interpretation of the presented results is confounding and additional lines of
190 evidence are necessary for a definitive conclusion.

191

192 **Key takeaways**

- 193 • Post-translational modifications (PTMs) can profoundly impact antibody detection
194 dynamics.
- 195 • Rapid PTM changes can complicate quantification in time-sensitive experiments.
- 196 • Understanding how PTMs or other alterations might affect your antibody's target epitope
197 is crucial for accurate data interpretation.
- 198 • Mutations can significantly influence PTM states and subsequent antibody recognition.
- 199 • Careful data analysis is required to distinguish between the effects of mutations on
200 protein expression versus detectability.

- 201 • Incomplete antibody stripping can further complicate interpretation; raw data inspection
202 is necessary to identify potential issues.

203

204 **CONSIDER HOW WESTERN BLOT STRIPPING CAN INFLUENCE DATA**
205 **QUANTIFICATION**

206

207 Incomplete antibody stripping is a common issue in Western blotting, particularly when
208 evaluating signaling cascades using phospho-specific antibodies. To accurately quantify both
209 phosphorylated and total protein levels on the same blot, it is necessary to effectively remove the
210 phospho-specific antibody prior to reprobing. Failure to do so can introduce residual signal,
211 leading to inaccurate quantification. FIGURE 2 demonstrates this with ERK1/2 phosphorylation:
212 even after stripping, residual phospho-ERK1/2 signal persists. In this experiment, we monitored
213 CXCL12-induced ERK1/2 phosphorylation in RPE cells overexpressing WT or mutant CXCR4.
214 The western blot was imaged both pre- and post-antibody stripping. As expected prior to
215 antibody stripping, CXCL12 robustly induces ERK1/2 phosphorylation (Figure 2). However,
216 while less pronounced, phospho-ERK1/2 staining persists after antibody stripping. Subsequent
217 staining with total ERK1/2 antibody of the same species or a similarly sized protein could lead to
218 inaccurate quantification.

219

220 One solution is to use total protein antibodies raised in a different species, eliminating the need
221 for stripping. However, limited resources and antibody availability can make this challenging.
222 Even when using primary antibodies raised in different hosts, stripping is necessary when
223 working with Horseradish peroxidase (HRP)-conjugated secondaries. This is essential to prevent
224 cross-reactivity between the HRP-conjugated secondary antibodies. While effective stripping is a
225 standard technique for laboratories routinely using Western blotting, various homemade buffers
226 exist alongside commercial options. The choice depends on your specific antibodies and
227 experimental needs. While imperfect, stripping and reprobing is often necessary and may not
228 change overall data interpretation.

229

230 One example of this is shown in FIGURE 1 lines 1-4, which illustrates how residual primary
231 antibody can impact quantification. UMB2 detection is negatively correlated with CXCR4 PTM.

232 Therefore, in this scenario the MYC antibody is the total signaling protein antibody and UMB2
233 is PTM sensitive. The MYC antibody (total protein) shows a visible decrease in detection at later
234 time points compared to UMB2 (PTM-sensitive). This is not biologically relevant as we have
235 previously confirmed that CXCR4 is not degraded or differentially extracted at the 20 min
236 stimulus time point (12). Since CXCR4 is stable at these time points, this decrease is likely due
237 to residual UMB2 antibody signal detected during MYC quantification. This highlights the
238 potential for underestimating PTMs in such cases.

239

240 To assess the extent of incomplete stripping, reprobe the freshly stripped blot with secondary
241 antibody alone. Residual primary antibodies will produce a similar banding pattern to the pre-
242 stripped blot and can influence quantification, particularly when comparing WT and mutant
243 proteins or knockdowns.

244

245 **Key Takeaways**

- 246 • Incomplete antibody stripping can impact Western blot quantification, particularly in
247 phospho-signaling studies and comparisons across experimental conditions.
- 248 • Using primary antibodies of different species can mitigate stripping issues, though
249 resource constraints may limit this approach.
- 250 • Reprobing a stripped blot with secondary antibody alone can help assess stripping
251 efficacy.
- 252 • Careful inspection of raw Western blot data is crucial for understanding potential
253 limitations and accurate data interpretation.

254

255 **EVALUATE ANTIBODY BANDING PATTERNS TO IDENTIFY POTENTIAL** 256 **QUANTIFICATION LIMITATIONS**

257

258 Careful analysis of antibody banding patterns in Western blots can reveal valuable information
259 about potential limitations in quantification. An important principle is that phospho-specific
260 antibodies should detect a subset of bands detected by the corresponding total protein antibody.
261 This reflects the fact that only a portion of the total protein is usually phosphorylated at any

262 given time. For instance, phospho-ERK1/2 antibodies should detect a subset of bands visualized
263 by the total ERK1/2 antibody.

264

265 Deviation from this pattern can signal issues with antibody specificity or experimental conditions
266 that could affect quantification. In FIGURE 1, the UMB2 antibody (PTM-sensitive) detects bands
267 within a subset of bands recognized by the MYC antibody (total protein), demonstrating
268 consistency with this principle. While visual inspection of bands offers preliminary insights, it is
269 essential to remember that apparent differences in band intensity may not directly translate to
270 actual changes in protein abundance. Densitometric analysis of Western blot images is crucial for
271 reliable quantification.

272

273 To minimize these timing discrepancies, particularly when comparing multiple samples, steps
274 like media removal and cell lysis should be performed on ice wherever possible. Precision
275 technologies like microfluidics offer another avenue for more accurate control over the timing of
276 stimulus and lysis.

277

278 The caveats described in this section, while focusing on CXCR4 PTM, illustrate principles
279 applicable to other Western blotting experiments and even related techniques like
280 immunofluorescence microscopy.

281

282 **Key Takeaways**

- 283 • Consider both antibody banding patterns and imaging sensitivity when interpreting
284 Western blot results.
- 285 • Visual band intensity differences may not always reflect true biological changes.
- 286 • Densitometric analysis provides a more reliable quantitative assessment of Western blot
287 data, especially when comparing samples with variations in signal strength.

288

289 **HOW DO WESTERN BLOTTING ASSUMPTIONS INFLUENCE QUANTIFICATION?**

290

291 The assumptions we rely on when interpreting Western blots can significantly impact
292 quantification and data interpretation. Here, we illustrate how these assumptions, particularly

293 those around data normalization, can influence interpretation. Reliable quantification depends on
294 working within the linear range of antibody detection, ensuring accurate comparisons between
295 samples.

296

297 The first step in quantification is data normalization, essential to account for technical and
298 experimental variability. Let us consider a hypothetical experiment (FIGURE 3A), comparing
299 control and treatment groups (e.g., inhibitor, knockdown, mutant protein) at 0- and 5-minutes
300 post-stimulus. Normalization strategies can have a significant impact in quantification:

301

- 302 • **Normalizing to the initial pre-treatment sample (FIGURE 3B (I)):** Pre-treatment signals
303 often have lower signal-to-noise ratios. Minor variations, when used as the basis of
304 normalization, can significantly amplify uncertainty in normalized values, especially if
305 signals fall outside the linear detection range.
- 306 • **Normalizing to the maximum value for each group (FIGURE 3B (II)):** This mitigates
307 uncertainty amplification but prevents direct comparison of maximum responses between
308 different experimental groups.
- 309 • **Normalizing to the control's maximum value (FIGURE 3B (III)):** This reduces inter-blot
310 variability and generally offers better signal-to-noise ratios. It also allows for
311 comparisons between treatments' maximum responses. However, this approach assumes
312 that the treatment does not significantly impact overall protein expression or other
313 signaling components.

314

315 The above examples highlight the importance of signals falling within the linear detection range
316 for reliable quantification. There are two preferred methods for accurate quantitation. First,
317 assessing linearity by determining the linear range for each antibody through antibody titrations
318 across a range of protein loads. Subsequent analyses should use values exclusively within this
319 range. Second, slope analysis by comparing slopes obtained by linear regression analysis of
320 integrated optical density for a range of protein loads provides the most robust quantitative
321 approach.

322

323 **Key Takeaways**

- 324 • The choice of normalization strategy can influence results and interpretation.
- 325 • Working within the linear range of your detection method is essential for accurate
326 quantification.
- 327 • Transparency in reporting normalization methods, along with explicit descriptions in
328 figure legends and methodology sections, is crucial.

329

330 **KEY CONSIDERATIONS FOR INTERPRETING CELL SIGNALING EXPERIMENTS** 331 **IN THE CONTEXT OF WESTERN BLOTTING**

332

333 The complexity of cellular signaling pathways underscores the need for careful interpretation of
334 Western blot data, particularly when interventions like knockdowns or mutations are involved.

335 Here are some key considerations:

- 336 • **Compensatory Mechanisms:** Cells often have multiple pathways regulating receptor
337 signaling and endocytosis. Knockdowns or mutations can trigger compensatory
338 mechanisms, obscuring the direct effects of your intervention. Whenever possible, design
339 experiments to decouple primary effects from potential compensatory changes.
- 340 • **Protein Multifunctionality:** Many proteins involved in endocytic trafficking have
341 multiple roles and localizations within the cell (30,31). Changes in protein levels or
342 mutations can have broader consequences beyond their intended target. Consider
343 potential secondary effects when interpreting results.
- 344 • **Cellular and Experimental Timescales:** When interpreting signaling data with short
345 timescales, it is essential to consider the practical limitations of experimental procedures.
346 Assume that it takes approximately 30 seconds to take cells from the incubator, remove
347 media, and prep samples for protein extraction. While a Western blot might indicate a "1-
348 minute stimulus", in reality is closer to 1.5 minutes – a 50% increase in stimulus time.
349 This variability might be less significant at later time points but can be a concern for early
350 time points in signaling cascades.
- 351 • **Receptor Regulation:** Signal transduction pathways are tightly regulated. Changes in
352 receptor localization, expression levels, or PTMs due to experimental manipulations can
353 influence downstream signaling in ways that might complicate quantification and
354 interpretation (32,33).

- 355 • **Spare Receptor Hypothesis:** Often, only a fraction of receptors need to be activated for
356 maximal signaling responses (34). This is important to consider when changes in receptor
357 expression or trafficking are part of the experimental design.
- 358 • **Methodological Rigor:** Whenever possible, use multiple, complementary approaches to
359 confirm your conclusions from Western blots analysis (35,36). This could involve
360 microscopy-based techniques to assess localization or alternative signaling readouts.

361

362 CONCLUSION

363 Scientific innovation thrives on creativity, the advancement of technologies, and the continuous
364 refinement of research methodologies. However, within this dynamic environment, there's a
365 heightened potential for honest yet irreproducible results. This lack of replicability stems from a
366 multitude of factors, including insufficient standardization in reporting experimental protocols,
367 flawed experimental design, statistical challenges, or biases in hypothesis testing. In this work,
368 we highlight another crucial factor influencing replicability: the fundamental assumptions
369 underlying the biological measurements themselves. We believe that incorporating principles of
370 metrology, the science of measurement, within receptor signaling could significantly reduce the
371 issues of replicability, and importantly, guide discoveries toward reaching scientific results with
372 rigor.

373

374 Throughout this article, we have revisited the core assumptions of Western blotting, emphasizing
375 important considerations that contribute to data uncertainty. As biology transitions toward a
376 more quantitative field, achieving replicability between different research groups becomes the
377 cornerstone of scientific rigor. This demands greater responsibility across the scientific
378 community to uphold gold standards for reporting measurement protocols and associated
379 assumptions. While these standards will not impede novel or significant findings, they will
380 ensure that research results align with the presented conclusions. Additionally, we must develop
381 standardized methods and protocols for sharing measurements. While our focus was on Western
382 blotting, many of these core concepts extend to other methodologies commonly used in cell
383 signaling research and cell biology in general.

384

385

386 **ACKNOWLEDGEMENTS**

387 We would like to thank Dr. Justin Eilertsen (University of Michigan), Dr. Wylie Stroberg
388 (University of Alberta) and Hesso Farhan (Medical University of Innsbruck) for constructive
389 discussions.

390

391


392 **REFERENCES**

- 393 1. Plant AL, Locascio LE, May WE, Gallagher PD. Improved reproducibility by assuring
394 confidence in measurements in biomedical research. *Nat Methods*. 2014 Sep;11(9):895–8.
- 395 2. Plant AL, Becker CA, Hanisch RJ, Boisvert RF, Possolo AM, Elliott JT. How measurement
396 science can improve confidence in research results. *PLoS Biol*. 2018 Apr;16(4):e2004299.
- 397 3. BIPM. BIPM - Guide to the Expression of Uncertainty in Measurement (GUM) [Internet].
398 2008 [cited 2018 Oct 12]. Available from:
399 <https://www.bipm.org/en/publications/guides/gum.html>
- 400 4. Harvey CD, Ehrhardt AG, Cellurale C, Zhong H, Yasuda R, Davis RJ, et al. A genetically
401 encoded fluorescent sensor of ERK activity. *Proc Natl Acad Sci*. 2008 Dec
402 9;105(49):19264–9.
- 403 5. Malik R, Soh UJK, Trejo J, Marchese A. Novel Roles for the E3 Ubiquitin Ligase Atrophin-
404 interacting Protein 4 and Signal Transduction Adaptor Molecule 1 in G Protein-coupled
405 Receptor Signaling. *J Biol Chem*. 2012 Mar 16;287(12):9013–27.
- 406 6. Miura H, Matsuda M, Aoki K. Development of a FRET biosensor with high specificity for
407 Akt. *Cell Struct Funct*. 2014;39(1):9–20.
- 408 7. Davies R, Vogelsang P, Jonsson R, Appel S. An optimized multiplex flow cytometry
409 protocol for the analysis of intracellular signaling in peripheral blood mononuclear cells. *J*
410 *Immunol Methods*. 2016 Sep 1;436:58–63.
- 411 8. Eichel K, Zastrow M von. Subcellular Organization of GPCR Signaling. *Trends Pharmacol*
412 *Sci*. 2018 Feb 1;39(2):200–8.
- 413 9. Burnette WN. Western blotting : remembrance of past things. *Methods Mol Biol Clifton NJ*.
414 2009;536:5–8.
- 415 10. Wynn ML, Egbert M, Consul N, Chang J, Wu ZF, Meravajer SD, et al. Inferring Intracellular
416 Signal Transduction Circuitry from Molecular Perturbation Experiments. *Bull Math Biol*.
417 2018 May;80(5):1310–44.
- 418 11. Mimura-Yamamoto Y, Shinohara H, Kashiwagi T, Sato T, Shioda S, Seki T. Dynamics and
419 function of CXCR4 in formation of the granule cell layer during hippocampal development.
420 *Sci Rep*. 2017 Jul 17;7(1):5647.
- 421 12. DeNies MS, Rosselli-Murai LK, Schnell S, Liu AP. Clathrin Heavy Chain Knockdown
422 Impacts CXCR4 Signaling and Post-translational Modification. *Front Cell Dev Biol*.
423 2019;7:77.
- 424 13. DeNies MS, Smrcka AV, Schnell S, Liu AP. β -arrestin mediates communication between
425 plasma membrane and intracellular GPCRs to regulate signaling. *Commun Biol*. 2020 Dec
426 18;3(1):1–12.

- 427 14. Taylor SC, Berkelman T, Yadav G, Hammond M. A Defined Methodology for Reliable
428 Quantification of Western Blot Data. *Mol Biotechnol*. 2013 Nov;55(3):217–26.
- 429 15. Eaton SL, Hurtado ML, Oldknow KJ, Graham LC, Marchant TW, Gillingwater TH, et al. A
430 Guide to Modern Quantitative Fluorescent Western Blotting with Troubleshooting
431 Strategies. *J Vis Exp JoVE* [Internet]. 2014 Nov 20;(93). Available from:
432 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354265/>
- 433 16. Ghosh R, Gilda JE, Gomes AV. The necessity of and strategies for improving confidence in
434 the accuracy of western blots. *Expert Rev Proteomics*. 2014 Oct;11(5):549–60.
- 435 17. Janes KA. An analysis of critical factors for quantitative immunoblotting. *Sci Signal*. 2015
436 Apr 7;8(371):rs2–rs2.
- 437 18. Bell G. Quantifying western blots: none more black. *BMC Biol*. 2016 Dec;14(1):116.
- 438 19. Bass JJ, Wilkinson DJ, Rankin D, Phillips BE, Szewczyk NJ, Smith K, et al. An overview of
439 technical considerations for Western blotting applications to physiological research. *Scand J*
440 *Med Sci Sports*. 2017 Jan;27(1):4–25.
- 441 20. Kirshner ZZ, Gibbs RB. Use of the REVERT® total protein stain as a loading control
442 demonstrates significant benefits over the use of housekeeping proteins when analyzing
443 brain homogenates by Western blot: An analysis of samples representing different gonadal
444 hormone states. *Mol Cell Endocrinol*. 2018 Sep;473:156–65.
- 445 21. Butler TAJ, Paul JW, Chan EC, Smith R, Tolosa JM. Misleading Westerns: Common
446 Quantification Mistakes in Western Blot Densitometry and Proposed Corrective Measures.
447 *BioMed Res Int*. 2019 Jan 21;2019:1–15.
- 448 22. Pillai-Kastoori L, Schutz-Geschwender AR, Harford JA. A systematic approach to
449 quantitative Western blot analysis. *Anal Biochem*. 2020 Mar;593:113608.
- 450 23. Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE. Housekeeping proteins:
451 A preliminary study illustrating some limitations as useful references in protein expression
452 studies. *PROTEOMICS*. 2005 Feb;5(2):566–71.
- 453 24. Li R, Shen Y. An old method facing a new challenge: Re-visiting housekeeping proteins as
454 internal reference control for neuroscience research. *Life Sci*. 2013 Apr;92(13):747–51.
- 455 25. Dittmer A, Dittmer J. β -Actin is not a reliable loading control in Western blot analysis.
456 *ELECTROPHORESIS*. 2006 Jul 1;27(14):2844–5.
- 457 26. Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ. The use of total protein stains as
458 loading controls: An alternative to high-abundance single-protein controls in semi-
459 quantitative immunoblotting. *J Neurosci Methods*. 2008 Jul 30;172(2):250–4.
- 460 27. Gilda JE, Gomes AV. Stain-Free total protein staining is a superior loading control to β -actin
461 for Western blots. *Anal Biochem*. 2013 Sep 15;440(2):186–8.

- 462 28. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL. Site-specific
463 Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in
464 Differential Modulation of CXCR4 Signaling. *J Biol Chem*. 2010 Mar 5;285(10):7805–17.
- 465 29. Luo J, Busillo JM, Stumm R, Benovic JL. G Protein-Coupled Receptor Kinase 3 and Protein
466 Kinase C Phosphorylate the Distal C-Terminal Tail of the Chemokine Receptor CXCR4 and
467 Mediate Recruitment of β -Arrestin. *Mol Pharmacol*. 2017;91(6):554–66.
- 468 30. Liberali P, Pelkmans L. *Nature Cell Biology*. 2012 [cited 2018 Oct 8]. Towards quantitative
469 cell biology. Available from: <https://www.nature.com/articles/ncb2648>
- 470 31. Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, et al. A subcellular
471 map of the human proteome. *Science*. 2017 26;356(6340).
- 472 32. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, et al. Clathrin-
473 independent endocytosis of ubiquitinated cargos. *Proc Natl Acad Sci U S A*. 2005 Feb
474 22;102(8):2760–5.
- 475 33. Sigismund S, Algisi V, Nappo G, Conte A, Pascolutti R, Cuomo A, et al. Threshold-
476 controlled ubiquitination of the EGFR directs receptor fate. *EMBO J*. 2013 Jul
477 31;32(15):2140–57.
- 478 34. Brown L, Deighton NM, Bals S, Söhlmann W, Zerkowski HR, Michel MC, et al. Spare
479 receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the
480 human heart. *J Cardiovasc Pharmacol*. 1992 Feb;19(2):222–32.
- 481 35. Kaelin Jr WG. Publish houses of brick, not mansions of straw. *Nat News*. 2017 May
482 25;545(7655):387.
- 483 36. Munafò MR, Smith GD. Robust research needs many lines of evidence. *Nature*. 2018
484 Jan;553(7689):399.
- 485

486 **Figures**
487




488
489 **Figure 1:** Western blotting assumptions are not always true. Representative western blot of non-
490 post-translationally modified (UMB2) and total CXCR4 (MYC) detection for WT RPE cells
491 transferred with CXCR4 (WT) and serine mutant receptors (S338/39A and S324/25A). Total
492 Protein and GAPDH staining illustrate protein loading for each replicate. **Experimental**
493 **methods:** RPE cells overexpressing CXCR4 were grown to 75% confluence a treated with fresh
494 FBS (10%) supplemented media (Gibco PN: 11330-032) 24 hours before the experiment. Cells
495 were serum starved for 4 hours and treated with 12.5 nM CXCL12 (R&D Systems PN: 350-NS-
496 050) for the described time course. Lysates were extracted using RIPA buffer (Pierce PN: 89900)
497 supplemented with protease and phosphatase inhibitors (Thermo Scientific PN: and respectively)
498 and incubated ice for 20 minutes and centrifuged at 16,100g for 45 minutes at 4°C. Loading
499 buffer supplemented with beta mercaptoethanol was added to denature lysates and samples were
500 loaded on a 4-20% BioRad gel and transferred onto PVDF membranes using the iBlot system

501 mixed range transfer (Thermo Scientific). Total protein was quantified using the REVERT Total
502 Protein Stain (LiCor PN: 926-11016). Afterwards, blots were blocked with 5% BSA (Thermo
503 Scientific PN: 37520) in TBST for 1 hour and incubated with primary antibodies ms-GAPDH
504 (1:1000), rb-UMB2 (1:2000) overnight at 4°C. Blots were incubated with secondary antibodies
505 (Gt anti ms-700, gt anti rb-800) for 1 hour in 5% BSA in TBST and imaged using the LiCor
506 Odyssey SA Imaging System. Afterwards, blots were stripped using NewBlot stripping buffer
507 (LiCor PN:928-40032) per manufacture instructions and reprobbed with rb-MYC antibody
508 (1:5000) as described above. UMB2 antibody was purchased from ABCAM (PN: Ab124824),
509 MYC from Bethyl (PN: A190-105A) and GAPDH from Santa Cruz Biotechnology (PN: sc-
510 47724). Secondary antibodies were purchased from Invitrogen (PN: SA535571 and 35518).

511


512
513



514
515

Figure 2: Example of incomplete western blot stripping. Phospho-ERK1/2 detection pre and post-antibody stripping. Total ERK1/2 staining is shown as a loading control. **Experimental methods:** RPE cells overexpressing WT or mutant CXCR4 were grown to 75% confluence and treated with fresh FBS (10%) supplemented media (Gibco PN: 11330-032) 24 hours before the experiment. Cells were serum starved for 4 hours and treated with 12.5 nM CXCL12 (R&D Systems PN: 350-NS-050) for the described time course. Lysates were extracted using RIPA buffer (Pierce PN: 89900) supplemented with protease and phosphatase inhibitors (Thermo Scientific PN: and respectively) and incubated on ice for 20 minutes and centrifuged at 16,100g for 45 minutes at 4°C. Loading buffer supplemented with beta mercaptoethanol was added to denature lysates and samples were loaded on a 4-20% BioRad gel and transferred onto PVDF membranes using the iBlot system mixed range transfer (Thermo Scientific). Blots were blocked with 5% BSA (Thermo Scientific PN: 37520) in TBST for 1 hour and incubated with primary antibodies ms-Total-ERK1/2 (1:1000), rb-phospho-ERK1/2 (1:2000) in 5% BSA in TBST overnight at 4°C. Blots were incubated with secondary antibodies (Gt anti ms-700, gt anti rb-800) for 1 hour in 5% BSA in TBST and imaged using the LiCor Odyssey SA Imaging System. Afterwards, blots were stripped using NewBlot stripping buffer (LiCor PN:928-40032) and imaged again to determine antibody stripping efficacy. Total and phospho-ERK1/2 antibodies were purchased from Cell Signaling Technologies (PN: 9107S and 4370S respectively). Secondary antibodies were purchased from Invitrogen (PN: SA535571 and 35518).

535
536



537

538 **Figure 3:** Normalization methodology can influence result interpretation. (A) Hypothetical

539 western blot results for a control and treatment experiment. Circles diameters are representative

540 of western blot band intensities and are listed. (B) Quantification of hypothetical western blot

541 results illustrating that normalizing to samples with low signal to noise ratio can propagate error

542 throughout normalization and influence result interpretation. For this representation, noise was

543 assumed to be constant for each sample. (i) Hypothetical quantification of data when normalized

544 to the 0 min time point of each treatment (i.e. normalizing value: 0.1 and 0.01 for the control and

545 treatment respectively). (ii) Hypothetical quantification of data when normalized to 5-minute

546 time point of each condition (i.e. normalizing value: 1 and 0.91 for the control and treatment

547 respectively). (iii) Hypothetical quantification of data when normalized to the 5-minute time

548 point of the control condition (i.e. normalizing value: one for all samples).

549